Skip to content
Interagency Autism Coordinating Committee (IACC)
Autism Research Database
Project Element Element Description

Project Title

Project Title

Explore the pathogenic role of mTor signaling in chr16p11.2 microdeletion

Principal Investigator

Principal Investigator

Tian, Di

Description

Description

Chromosomal copy number variations (CNVs) are common genetic abnormalities in autism spectrum disorder (ASD) and have been identified in approximately 10 percent of individuals with ASD. Currently, there is a knowledge gap in the understanding of the molecular and synaptic mechanisms underlying CNV-associated ASD. A microdeletion at human chromosome 16p11.2 is the most common ASD-linked CNV, and accounts for 0.5-1.0 percent of all ASD cases. The typical neurological abnormalities in individuals with 16p11.2 microdeletion are ASD, intellectual disability, language deficits, anxiety, attention deficit hyperactivity disorder and epilepsy. The high prevalence of disruptions in social, communication and behavioral domains among individuals carrying 16p11.2 microdeletions indicates that this region holds significant relevance for ASD and ASD-related phenotypes. Di Tian and his colleagues recently characterized a mouse model of the 16p11.2 microdeletion (16p11.2df/+). These mice have altered mGluR5-dependent hippocampal plasticity and display several behavioral phenotypes associated with dysfunction of the hippocampus1. Tian’s team will further assess this mouse model to gain additional mechanistic insights into the neurobiological consequences of the 16p11.2 microdeletion. The PI3K-Akt-mTOR signaling pathway is commonly affected in neurodevelopmental disorders; however, its role in 16p11.2 microdeletion has not been explored. Tian and his team hypothesize that 16p11.2 microdeletion results in aberrant mTOR signaling, leading to abnormal morphological and behavioral phenotypes. To test this hypothesis, the team will modify the PI3K-Akt-mTOR pathway and assess morphological and behavioral outcomes. Results supporting this hypothesis could suggest that individuals with 16p11.2 microdeletion might benefit from treatments targeting mTOR signaling. The long-term goal of this project is to provide new insights into ASD disease mechanisms and help inform new strategies for effective treatments. References: 1. Tian D. et al. Nat. Neurosci. 18, 182-184 (2015) PubMed

Funder

Funder

Simons Foundation

Funding Country

Funding Country

United States

Fiscal Year Funding

Fiscal Year Funding

0

Current Award Period

Current Award Period

2015-2016

Strategic Plan Question

Strategic Plan Question

Question 2: What is the Biology Underlying ASD?

Funder’s Project Link

Funder’s Project Link

External Project Page Go to website disclaimer

Institution

Institution

Children's Hospital Los Angeles

Institute Location

Institute Location

United States

Project Number

Project Number

377840

Government or Private

Government or Private

Private

History/Related Projects

History/Related Projects

Explore the pathogenic role of mTor signaling in chr16p11.2 microdeletion | 60000 | 2015 | 377840

Back to Top